• Rinath Jeselsohn, Carmine De Angelis, Myles Brown, and Rachel Schiff.
• Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. rinath_jeselsohn@dfci.harvard.edu.
• Curr Oncol Rep. 2017 May 1; 19 (5): 35.

AbstractRecurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number of patients with metastatic ER+ breast cancer and evolve under the selective pressure of endocrine treatments. In this review, we evaluate the current understanding of the biological and clinical significance of these mutations. The preclinical studies revealed that these mutations lead to constitutive ligand-independent activity, indicating resistance to aromatase inhibitors and decreased sensitivity to tamoxifen and fulvestrant. Retrospective analyses of ESR1 mutations in baseline plasma circulating tumor DNA from completed clinical trials suggest that these mutations are prognostic and predictive of resistance to aromatase inhibitors in metastatic disease. Currently, we are lacking prospective studies to confirm these results and to determine the optimal treatment combinations for patients with the ESR1 mutations. In addition, the clinical development of novel agents to overcome resistance engendered by these mutations is also needed.

37 keywords...

hide…